Lake Street Capital Reiterates "Hold" Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report)'s stock had its "hold" rating restated by equities researchers at Lake Street Capital in a research note issued on Monday, Marketbeat.com reports. They presently have a $4.10 price objective on the stock, down from their previous price objective of $7.00. Lake Street Capital's price target indicates a potential upside of 3.14% from the company's current price.

Several other equities research analysts have also issued reports on CKPT. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th. D. Boral Capital reaffirmed a "buy" rating and issued a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a report on Monday.

Checkpoint Therapeutics Price Performance

Shares of CKPT traded down $0.02 during midday trading on Monday, reaching $3.98. The stock had a trading volume of 3,657,487 shares, compared to its average volume of 2,521,279. The firm's 50 day moving average price is $3.16 and its 200-day moving average price is $3.11. Checkpoint Therapeutics has a 52 week low of $1.38 and a 52 week high of $4.50. The company has a market capitalization of $194.11 million, a P/E ratio of -2.16 and a beta of 1.41.

Insider Transactions at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at $11,891,309.85. This represents a 0.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 582,336 shares of company stock valued at $2,156,801. Corporate insiders own 2.10% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in Checkpoint Therapeutics by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 445,111 shares of the company's stock valued at $1,425,000 after buying an additional 17,460 shares in the last quarter. 683 Capital Management LLC bought a new stake in Checkpoint Therapeutics in the 4th quarter valued at approximately $522,000. HB Wealth Management LLC boosted its position in Checkpoint Therapeutics by 96.9% during the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company's stock worth $513,000 after acquiring an additional 75,560 shares during the last quarter. PVG Asset Management Corp lifted its position in shares of Checkpoint Therapeutics by 9.2% in the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company's stock worth $336,000 after purchasing an additional 12,676 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company's stock valued at $291,000 after acquiring an additional 80,000 shares during the last quarter. Institutional investors and hedge funds own 22.00% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.